BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 29936529)

  • 21. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
    Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
    J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A; Schweitzer MA; Häring HU;
    Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
    Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
    Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 25. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
    Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
    Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is NPH associated with fewer adverse events than analog basal insulin for adults with T2D?
    Lyon C; Iruku S; Hoss M; DeSanto K; Guthmann R
    J Fam Pract; 2021 May; 70(4):E5-E6. PubMed ID: 34339367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
    Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
    J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K; Molz K; Kerner W; Karges W; Lang W; Dapp A; Schütt M; Best F; Seufert J; Holl RW
    Diabetes Metab Res Rev; 2014 Jul; 30(5):395-404. PubMed ID: 24302583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.
    Toyoda M; Kimura M; Yamamoto N; Miyauchi M; Umezono T; Suzuki D
    J Nephrol; 2012; 25(6):989-95. PubMed ID: 22307438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
    Polonsky W; Traylor L; Gao L; Wei W; Ameer B; Stuhr A; Vlajnic A
    J Diabetes Complications; 2017 Mar; 31(3):562-568. PubMed ID: 28040350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Cumulative Multimorbidity, Glycemic Control, and Medication Use With Hypoglycemia-Related Emergency Department Visits and Hospitalizations Among Adults With Diabetes.
    McCoy RG; Lipska KJ; Van Houten HK; Shah ND
    JAMA Netw Open; 2020 Jan; 3(1):e1919099. PubMed ID: 31922562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial.
    Fishel Bartal M; Ward C; Blackwell SC; Ashby Cornthwaite JA; Zhang C; Refuerzo JS; Pedroza C; Lee KH; Chauhan SP; Sibai BM
    Am J Obstet Gynecol; 2021 Jul; 225(1):87.e1-87.e10. PubMed ID: 33865836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
    Dhital SM; Shenker Y; Meredith M; Davis DB
    Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
    Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment persistence in the use of basal insulins in Poland and Germany
.
    Rathmann W; Czech M; Franek E; Kostev K
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
    Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
    Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.